Executive officer

Daniel Salvadori

Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products·Abbott Laboratories

About

Daniel Salvadori has served as Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products of Abbott since 2021.

He previously served as Executive Vice President, Nutritional Products from 2017 to 2021 and was elected a corporate officer in 2014.

Since 2021
Age 47
Tenure 5 yrs

Also at Abbott Laboratories

NM Nita Ahuja, M.D. Director RM Robert J. Alpern, M.D. Director CB Claire Babineaux-Fontenot Director SP Sally E. Blount, Ph.D. Director RF Robert B. Ford Chairman of the Board and Chief Executive Officer; Director PG Paola Gonzalez Director

Roles

Organization Role Dates Details
Abbott Laboratories Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 2021–present Current role
Abbott Laboratories Executive Vice President, Nutritional Products 2017 to 2021
Abbott Laboratories Senior Vice President, Established Pharmaceuticals, Latin America
CFR Pharmaceuticals Chief Executive Officer, LATAM Prior to joining Abbott.

Related

Company Abbott Laboratories Company hub Person Nita Ahuja, M.D. Director Person Robert J. Alpern, M.D. Director Person Claire Babineaux-Fontenot Director Person Sally E. Blount, Ph.D. Director Person Robert B. Ford Chairman of the Board and Chief Executive Officer; Director Person Paola Gonzalez Director Person Michelle A. Kumbier Director Person Darren W. McDew Director Person Nancy McKinstry Lead Independent Director Person Michael G. O'Grady Director Person Michael F. Roman Director Person Daniel J. Starks Director Deal Abbott Laboratories Advanced Medical Optics 2009 Deal page Deal Abbott Laboratories Alere 2017 Deal page Deal Abbott Laboratories Basf S Pharmaceutical Business Knoll 2001 Deal page
Source: Abbott Laboratories SEC filings and official company website

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo